Using Compl-AI to Predict Early Medication Dropout in Opioid Use Disorder Treatment
Part of Mental health clinical trials.
This study tests Compl-AI, a tool that helps predict if someone with opioid use disorder might stop their medication early. By identifying this risk, doctors can offer extra support to help patients stay on track.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have opioid use disorder (diagnosed by a doctor using standard criteria).
- You must be eligible to start medication for opioid use disorder or already be taking it.
- You must be able to understand and agree to the study by signing a consent form.
- You cannot have severe cognitive impairment (like memory or thinking problems) that would prevent you from giving consent.
- You cannot be already enrolled in another study or program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a flexible, personalized approach to treating opioid use disorder (OUD) that adjusts over time based on how you're doing. It aims to find the best treatment plan to help you recover and stay healthy.
This study tests if a smartphone app can help people taking medications for opioid use disorder and who also have alcohol use disorder. You will use the app for 6 months and provide feedback through surveys and saliva drug tests.
This Phase 3 study tests whether using smartphones can help people with opioid-use disorder stick with treatment and recover more successfully. It focuses on people starting or already in treatment using methadone or buprenorphine, with support delivered through the study app or messages.
This study looks at how people with opioid use disorder remember personal events. You'll do tasks on a cellphone and at home while taking medication for opioid use disorder.
This study tests whether AI and peer coaching can help Black and Latinx people who use opioids start buprenorphine treatment and reduce racial disparities. It's designed for people in New York City who are interested in starting this medication.
This early-stage study tests a new approach for opioid use disorder in adults. It aims to understand safety and how the treatment may work in people with opioid addiction.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.